http://hl7.org/fhir/uv/ebm/Citation/179627
type: Citation
node role: treeRoot
id:
  v: 179627
meta:
  version id:
    v: 21
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Citation 179627 version: 21; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: Citation 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. identifier: FEvIR Object Identifier/179627, https://pubmed.ncbi.nlm.nih.gov/19091394, <a href="http://terminology.hl7.org/7.0.1/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt #xD;#xA;#xD;#xA;This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: #xD;#xA;#xD;#xA;Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.#xD;#xA;#xD;#xA;This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.29 version: 1.0.0-ballot3 title: 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. status: Active date: 2026-01-08 11:24:31+0000 author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: HL7 International / Clinical Decision Support contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform …
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Widmark
    given:
      v: Anders
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Klepp
    given:
      v: Olbjørn
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Solberg
    given:
      v: Arne
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Damber
    given:
      v: Jan-Erik
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Angelsen
    given:
      v: Anders
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Fransson
    given:
      v: Per
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Lund
    given:
      v: Jo-Asmund
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Tasdemir
    given:
      v: Ilker
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Hoyer
    given:
      v: Morten
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Wiklund
    given:
      v: Fredrik
contained: Practitioner
  id:
    v: contributor10
  name:
    family:
      v: Fosså
    given:
      v: Sophie D
contained: Organization
  id:
    v: contributor11
  name:
    v: Scandinavian Prostate Cancer Group Study 7
contained: Organization
  id:
    v: contributor12
  name:
    v: Swedish Association for Urological Oncology 3
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: Citation
      l: Citation
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D000726
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D003131
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D005485
    free to share:
      v: true
    component:
      classifier:
        coding: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D011468
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier:
      coding: D011471
    free to share:
      v: true
    component:
      classifier:
        coding: Q000188
    component:
      classifier:
        coding: Q000401

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D003131

v: Combined Modality Therapy

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D005485

v: Flutamide

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000627
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011468

v: Prostatectomy

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011471

v: Prostatic Neoplasms

v: false

v: qualifier

v: is not a major topic

v: qualifier

Q000188
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000188
display:
  v: drug therapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: qualifier

Q000401
system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000401
display:
  v: mortality

type:
  text:
    v: is Major topic
classifier:
  coding:
    system:
      v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
      l: Thesaurus.owl
    code:
      v: C49487
    display:
      v: No

type:
  text:
    v: qualifier
classifier:
  coding: Q000532
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: Q000532
    display:
      v: radiotherapy
component:
  type:
    text:
      v: is Major topic
  classifier:
    coding:
      system:
        v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
        l: Thesaurus.owl
      code:
        v: C49488
      display:
        v: Yes

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D012720
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D012720
    display:
      v: Severity of Illness Index
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D016019
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016019
    display:
      v: Survival Analysis
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179627
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 19091394

system:
  v: urn:ietf:rfc:3986
  l: 3986
value:
  v: urn:oid:2.16.840.1.113883.4.642.40.44.15.29

v: 1.0.0-ballot3

v: 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

v: active

v: 2026-01-08T11:24:31+00:00

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: HL7 International / Clinical Decision Support

name:
  v: HL7 International / Clinical Decision Support
telecom:
  system:
    v: url
  value:
    v: http://www.hl7.org/Special/committees/dss

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

coding:
  system:
    v: http://unstats.un.org/unsd/methods/m49/m49.htm
    l: m49.htm
  code:
    v: 001
  display:
    v: World

v: 2009-02-05

v: 2022-03-30

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2008-12-19T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2008-12-19T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2009-02-06T09:00:00.000Z

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 19091394
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1016/S0140-6736(08)61815-2
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: pii
  value:
    v: S0140-6736(08)61815-2
related identifier:
  value:
    v: ISRCTN01534787
  assigner:
    display:
      v: ISRCTN
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  text:
    v: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **BACKGROUND:** Several studies have shown the efficacy of endocrine therapy in combination with radiotherapy in high-risk prostate cancer. To assess the effect of radiotherapy, we did an open phase III study comparing endocrine therapy with and without local radiotherapy, followed by castration on progression. **METHODS:** This randomised trial included men from 47 centres in Norway, Sweden, and Denmark. Between February, 1996, and December, 2002, 875 patients with locally advanced prostate cancer (T3; 78%; PSA<70; N0; M0) were centrally randomly assigned by computer to endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide; 439 patients), or to the same endocrine treatment combined with radiotherapy (436 patients). The primary endpoint was prostate-cancer-specific survival, and analysis was by intention to treat. This study is registered as an international standard randomised controlled trial, number ISRCTN01534787. **FINDINGS:** After a median follow-up of 7.6 years, 79 men in the endocrine alone group and 37 men in the endocrine plus radiotherapy group had died of prostate cancer. The cumulative incidence at 10 years for prostate-cancer-specific mortality was 23.9% in the endocrine alone group and 11.9% in the endocrine plus radiotherapy group (difference 12.0%, 95% CI 4.9-19.1%), for a relative risk of 0.44 (0.30-0.66). At 10 years, the cumulative incidence for overall mortality was 39.4% in the endocrine alone group and 29.6% in the endocrine plus radiotherapy group (difference 9.8%, 0.8-18.8%), for a relative risk of 0.68 (0.52-0.89). Cumulative incidence at 10 years for PSA recurrence was substantially higher in men in the endocrine-alone group (74.7%vs 25.9%, p<0.0001; HR 0.16; 0.12-0.20). After 5 years, urinary, rectal, and sexual problems were slightly more frequent in the endocrine plus radiotherapy group. **INTERPRETATION:** In patients with locally advanced or high-risk local prostate …
relates to:
  type:
    v: correction-in
  classifier:
    coding: D016425
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016425
      display:
        v: Published Erratum
      user selected:
        v: false
  citation:
    v: Lancet. 2009 Apr 4;373(9670):1174
relates to:
  type:
    v: comment-in
  classifier:
    coding: D016420
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Lancet. 2009 Jan 24;373(9660):274-6. doi: 10.1016/S0140-6736(08)61816-4.
relates to:
  type:
    v: comment-in
  classifier:
    coding: D016420
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Nat Rev Urol. 2009 May;6(5):250-1. doi: 10.1038/nrurol.2009.56.
relates to:
  type:
    v: comment-in
  classifier:
    coding: D016420
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Ann Intern Med. 2009 Jun 16;150(12):JC6-6. doi: 10.7326/0003-4819-150-12-200906160-02006.
relates to:
  type:
    v: comment-in
  classifier:
    coding: D016420
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Eur Urol. 2009 May;55(5):1240. doi: 10.1016/j.eururo.2009.01.059.
relates to:
  type:
    v: comment-in
  classifier:
    coding: D016420
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Eur Urol. 2009 May;55(5):1239-40. doi: 10.1016/j.eururo.2009.01.058.
publication form:
  published in:
    identifier:
      system:
        v: https://portal.issn.org
        l: portal.issn.org
      value:
        v: 1474-547X
    identifier:
      system:
        v: https://www.issn.org/services/online-services/access-to-the-ltwa/
        l: access-to-the-ltwa
      value:
        v: Lancet
    identifier:
      system:
        v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
        l: the-issn-l-for-publications-on-multiple-media
      value:
        v: 0140-6736
    identifier:
      system:
        v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
        l: contructitleabbre.html
      value:
        v: Lancet
    identifier:
      system:
        v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
        l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      value:
        v: 2985213R
    title:
      v: Lancet (London, England)
    publisher location:
      v: England
  cited medium:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-medium
        l: cited-medium
      code:
        v: internet
      display:
        v: Internet
  volume:
    v: 373
  issue:
    v: 9660

v: D020492

v: Periodical

system:
  v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
  l: issn
code:
  v: Electronic
display:
  v: Electronic

v: Electronic ISSN Type

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISOAbbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISSN Linking

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: Medline Title Abbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: NLM Unique ID

v: 2009-01-24

v: 301-8

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2008-12-16

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/19091394/
  l: https://pubmed.ncbi.nlm.nih.gov/19091394/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1016/S0140-6736(08)61815-2
  l: S0140-6736(08)61815-2

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Print-Electronic
    display:
      v: Print Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier:
  coding: D000726
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000726
    display:
      v: Androgen Antagonists
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 76W6J0943E
    user selected:
      v: false
  coding: D005485
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D005485
    display:
      v: Flutamide
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier:
  coding: D017428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017428
    display:
      v: Clinical Trial, Phase III
    user selected:
      v: false
classifier:
  coding: D016428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier:
  coding: D016448
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016448
    display:
      v: Multicenter Study
    user selected:
      v: false
classifier:
  coding: D016449
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016449
    display:
      v: Randomized Controlled Trial
    user selected:
      v: false
classifier:
  coding: D013485
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D013485
    display:
      v: Research Support, Non-U.S. Gov't
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Widmark A
  forename initials:
    v: A
  affiliation:
    display:
      v: Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Klepp O
  forename initials:
    v: O
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Solberg A
  forename initials:
    v: A
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Damber JE
  forename initials:
    v: JE
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Angelsen A
  forename initials:
    v: A
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Fransson P
  forename initials:
    v: P
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Lund JA
  forename initials:
    v: JA
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Tasdemir I
  forename initials:
    v: I
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Hoyer M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Wiklund F
  forename initials:
    v: F
entry:
  contributor:
    l: contributor10
    reference:
      v: #contributor10
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Fosså SD
  forename initials:
    v: SD
entry:
  contributor:
    l: contributor11
    reference:
      v: #contributor11
    type:
      v: Organization
      l: Organization
    display:
      v: Scandinavian Prostate Cancer Group Study 7
entry:
  contributor:
    l: contributor12
    reference:
      v: #contributor12
    type:
      v: Organization
      l: Organization
    display:
      v: Swedish Association for Urological Oncology 3